Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage biotechnology company with a market capitalization of $1.8 billion, announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen) in patients with myotonic dystrophy type 1 (DM1), showing clinically meaningful improvements in function and strength at the selected registrational dose.
The data, presented at the 30th Annual International Congress of the World Muscle Society, demonstrated improvements across multiple clinical measures in adults with DM1 who received the 6.8 mg/kg dose administered every eight weeks
The results showed sustained improvement in hand myotonia, as measured by video hand opening time. Functional improvements were observed in multiple tests including the 10-Meter Walk/Run Test, 5 Times Sit to Stand Test, and the 9-Hole Peg Test, which measures upper limb function.
Strength assessments revealed improvements across both upper and lower extremities, including hand grip strength, elbow flexion and extension, ankle dorsiflexion, and knee flexion and extension.
Patient-reported outcomes showed meaningful improvements in the Myotonic Dystrophy Health Index, including in subscales assessing cognitive impairment, sleep disturbances, fatigue, communication, emotional issues, and pain. New data also indicated improvements in mobility, ability to perform activities, and upper extremity function.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.